• Molecular NameCefuroxime_axetil
  • SynonymNA
  • Weight510.48
  • Drugbank_IDN/A
  • ACS_NO64544-07-6
  • Show 3D model
  • LogP (experiment)0.89
  • LogP (predicted, AB/LogP v2.0)0.8
  • pkaN/A
  • LogD (pH=7, predicted)0.8
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-4.36
  • LogSw (predicted, AB/LogsW2.0)0.66
  • Sw (mg/ml) (predicted, ACD/Labs)0.02
  • No.of HBond Donors3
  • No.of HBond Acceptors14
  • No.of Rotatable Bonds12
  • TPSA214.36
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAnti-Bacterial Agents
  • Absorption_value44.0
  • Absorption (description)Cefuroxime axetil is absorbed from the gastrointestinal tract and rapidly hydrolyzed by nonspecific esterases in the intestinal mucosa and blood to cefuroxime.
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmAfter oral administration, cefuroxime axetil is absorbed from the gastrointestinal tract and rapidly hydrolyzed by nonspecific esterases in the intestinal mucosa and blood to cefuroxime. Cefuroxime is subsequently distributed throughout the extracellular fluids. The axetil moiety is metabolized to acetaldehyde and acetic acid.
  • Half life1.2~1.9 hours depending on dose of cefuroxime axetil administred with milk or milk products.
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityThe adverse reactions with incidence more than 1% include diarrhea, nausea, vomiting, eosonophilia, transient elevation in AST, ALT, LDH.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A